Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 55.36M | 54.46M | 53.32M | 51.42M | 49.91M |
| Total Other Revenue | 4.65M | 4.62M | 4.57M | 4.57M | 4.60M |
| Total Revenue | 60.01M | 59.09M | 57.88M | 55.99M | 54.51M |
| Cost of Revenue | 5.50M | 5.30M | 5.08M | 4.76M | 4.47M |
| Gross Profit | 54.51M | 53.78M | 52.80M | 51.23M | 50.04M |
| SG&A Expenses | 17.60M | 18.34M | 18.98M | 19.03M | 19.19M |
| Depreciation & Amortization | 774.80K | 764.30K | 749.10K | 700.30K | 655.20K |
| Other Operating Expenses | -370.60K | -370.60K | -370.60K | -193.10K | -16.10K |
| Total Operating Expenses | 26.44M | 26.28M | 25.98M | 25.53M | 25.25M |
| Operating Income | 33.58M | 32.80M | 31.90M | 30.46M | 29.26M |
| Income Before Tax | 38.11M | 35.79M | 33.29M | 31.81M | 30.61M |
| Income Tax Expenses | 12.55M | 11.25M | 9.88M | 10.13M | 10.48M |
| Earnings from Continuing Operations | 25.56 | 24.54 | 23.40 | 21.68 | 20.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.56M | 24.54M | 23.40M | 21.68M | 20.13M |
| EBIT | 33.58M | 32.80M | 31.90M | 30.46M | 29.26M |
| EBITDA | 34.10M | 33.31M | 32.40M | 30.90M | 29.65M |
| EPS Basic | 0.51 | 0.49 | 0.47 | 0.44 | 0.41 |
| Normalized Basic EPS | 0.48 | 0.45 | 0.42 | 0.40 | 0.39 |
| EPS Diluted | 0.51 | 0.48 | 0.46 | 0.42 | 0.39 |
| Normalized Diluted EPS | 0.47 | 0.44 | 0.41 | 0.39 | 0.37 |
| Average Basic Shares Outstanding | 200.38M | 199.86M | 199.34M | 198.63M | 197.91M |
| Average Diluted Shares Outstanding | 201.47M | 202.79M | 204.11M | 205.51M | 206.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 6.47% | 6.70% | 6.89% | 7.44% | 8.02% |